Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05174767 · ClinicalTrials.gov registry record · NA
PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection
A NA study of Acute Aortic Dissection, sponsored by Artivion.
- Active
- Registry status
- NA
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT05174767: Active NA study of Acute Aortic Dissection, sponsored by Artivion.
NCT05174767 is a NA study of Acute Aortic Dissection that is active but no longer recruiting, run by Artivion. The registered enrollment target is 115 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05174767, a NA study of Acute Aortic Dissection, is active but no longer recruiting, sponsored by Artivion.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.
Primary Outcome
Patients experiencing at least one of the following MAEs: 1. All-cause mortality (ACM) 2. New disabling stroke 3. New onset renal failure requiring dialysis 4. Myocardial infarction (MI)
Conditions Studied
Interventions
- DEVICE AMDS
Study Locations (20)
New York
- Mount Sinai Hospital - New York
- Columbia University Irving Medical Center/New York Presbyterian Hospital - New York
- Northwell - New York
- Montefiore Einstein Medical - The Bronx
California
- University of Southern California - Los Angeles
- Stanford University - Palo Alto
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
Connecticut
- Hartford Hospital - Hartford
Florida
- University of Florida - Gainesville
Georgia
- Emory University Medical Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2022-05-27 |
| Est. Completion | 2029-12-06 |
| Phase | NA |
What the registry record for NCT05174767 still lists
NCT05174767 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Acute Aortic Dissection appearing as the primary indexed condition, and to 1 intervention - of which AMDS is the first listed.
NCT05174767 names 20 study sites across 15 states, led by New York, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05174767 about?
NCT05174767 is a clinical study titled "PERSEVERE- a Trial to Evaluate AMDS in Acute DeBakey Type I Dissection". Prospective, non-randomized, multicenter clinical investigation to assess the safety and effectiveness of AMDS in the treatment of patients with acute DeBakey type I dissection, with evidence of malperfusion, through open surgical repair.
What is the current status of trial NCT05174767?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 115 participants. The study started on 2022-05-27. Estimated completion is 2029-12-06.
What conditions does trial NCT05174767 study?
This clinical trial studies the following conditions: Acute Aortic Dissection.
What interventions are being tested in trial NCT05174767?
The interventions under investigation include: AMDS (DEVICE).
Who is sponsoring clinical trial NCT05174767?
This trial is sponsored by Artivion, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05174767 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Aortic Dissection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05174767's enrollment target sits among peer trials
115 810th of 2000 higher than 1,190 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI